You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 13, 2025

Drug Price Trends for SODIUM POLYSTYRENE SULF POWDER


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for SODIUM POLYSTYRENE SULF POWDER

Average Pharmacy Cost for SODIUM POLYSTYRENE SULF POWDER

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug NameNDCPrice/Unit ($)UnitDate
SODIUM POLYSTYRENE SULF POWDER 10702-0036-45 0.12707 GM 2025-03-19
SODIUM POLYSTYRENE SULF POWDER 11534-0166-44 0.12707 GM 2025-03-19
SODIUM POLYSTYRENE SULF POWDER 46287-0012-16 0.12707 GM 2025-03-19
SODIUM POLYSTYRENE SULF POWDER 10702-0036-45 0.11272 GM 2025-02-19
>Drug Name>NDC>Price/Unit ($)>Unit>Date
Showing 1 to 4 of 4 entries

Sodium Polystyrene Sulfonate Powder Market Analysis and Price Projections

Market Overview

The sodium polystyrene sulfonate powder market is experiencing significant growth, driven primarily by the increasing incidence of hyperkalemia, a condition characterized by high blood potassium levels. Here is a comprehensive analysis of the market, including its current state, future projections, and key factors influencing its growth.

Market Size and Growth Projections

As of 2023, the sodium polystyrene sulfonate powder market was valued at USD 200 million. It is anticipated to grow at a Compound Annual Growth Rate (CAGR) of 6.5% from 2024 to 2031, reaching a projected value of USD 350 million by 2031[1][3][5].

Key Drivers of Market Growth

Increasing Incidence of Hyperkalemia

Hyperkalemia is a common condition, especially among patients with chronic kidney disease, heart failure, and those taking certain blood pressure medications. The rising prevalence of these underlying conditions is a major driver of the market. Hyperkalemia affects nearly 8% of hospitalized U.S. patients and is estimated to occur in 2-3% of the general population and 1-10% of hospitalized patients[5].

Technological Advancements

Continuous developments in formulation and delivery techniques enhance patient compliance and outcomes. Improved drug designs and technological advancements in medicine make sodium polystyrene sulfonate more effective and safer, thereby increasing its marketability[1].

Growing Awareness and Diagnosis

Increasing awareness among patients and healthcare professionals about hyperkalemia and its management is another significant factor. Better diagnostic tools and more widespread recognition of chronic kidney disorders contribute to the growing demand for sodium polystyrene sulfonate powder[1][5].

Market Segmentation

By Application

The market is segmented based on various applications, including:

  • Hyperkalemia treatment: The primary use of sodium polystyrene sulfonate powder.
  • Chronic kidney disease: Patients with chronic kidney disease are at a higher risk of developing hyperkalemia.
  • Acute kidney injury: This condition can also lead to elevated potassium levels.
  • Dialysis patients: These patients often require management of electrolyte imbalances.
  • Electrolyte imbalance: General use for correcting potassium levels in the body[1][3][5].

By Product

The market is also segmented by product type:

  • Sodium polystyrene sulfonate powder
  • Sodium polystyrene sulfonate oral suspension
  • Sodium polystyrene sulfonate enema[1][3].

By Geography

The market is analyzed across various geographical regions:

  • North America: Expected to hold significant promise due to advanced healthcare infrastructure and increased awareness about chronic kidney disorders.
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa[1][3][5].

Price Projections

Current Pricing

The cost for sodium polystyrene sulfonate oral and rectal powder is approximately $11 for a supply of 15 grams, depending on the pharmacy. For larger quantities, the price per unit decreases, with 150 grams (10 x 15 grams) costing around $26.88 and 453.6 grams costing about $62.05[2].

Future Pricing Trends

While specific future price projections are not provided, the overall market growth and increasing demand are likely to influence pricing. However, the cost-effectiveness of sodium polystyrene sulfonate powder, especially compared to other treatments, is expected to maintain its competitive pricing[1][3][5].

Impact of COVID-19

The COVID-19 pandemic has had a significant impact on various aspects of the healthcare industry, including supply chains and market dynamics. However, the essential nature of sodium polystyrene sulfonate powder in treating hyperkalemia has ensured continued demand despite the challenges posed by the pandemic[5].

Competitive Scenario

The market is competitive, with several key players:

  • Concordia Pharmaceuticals
  • CMP Pharma
  • Mylan
  • Glenmark Pharmaceuticals
  • Sanofi
  • Teva Pharmaceuticals
  • Apotex
  • Aurobindo Pharma
  • Zydus Cadila
  • Akorn[1].

These companies are focused on improving formulations, enhancing patient compliance, and expanding their market presence through strategic initiatives.

Key Takeaways

  • The sodium polystyrene sulfonate powder market is projected to grow from USD 200 million in 2023 to USD 350 million by 2031 at a CAGR of 6.5%.
  • The increasing incidence of hyperkalemia, technological advancements, and growing awareness are key drivers of market growth.
  • The market is segmented by application, product type, and geography.
  • Current pricing is around $11 for 15 grams, with larger quantities offering lower per-unit costs.
  • The COVID-19 pandemic has had a significant impact on the healthcare industry but has not deterred the demand for sodium polystyrene sulfonate powder.

FAQs

What is the primary use of sodium polystyrene sulfonate powder?

Sodium polystyrene sulfonate powder is primarily used to treat hyperkalemia, a condition characterized by high blood potassium levels.

How is the sodium polystyrene sulfonate powder market expected to grow?

The market is expected to grow at a CAGR of 6.5% from 2024 to 2031, reaching USD 350 million by 2031.

What are the key drivers of the sodium polystyrene sulfonate powder market?

The key drivers include the increasing incidence of hyperkalemia, technological advancements in drug formulations, and growing awareness among patients and healthcare professionals.

What are the different product types of sodium polystyrene sulfonate?

The product types include sodium polystyrene sulfonate powder, oral suspension, and enema.

How has the COVID-19 pandemic affected the sodium polystyrene sulfonate powder market?

The pandemic has had a significant impact on the healthcare industry, but the essential nature of sodium polystyrene sulfonate powder has ensured continued demand.

What is the current pricing for sodium polystyrene sulfonate powder?

The current cost is approximately $11 for a supply of 15 grams, depending on the pharmacy.

Who are the key players in the sodium polystyrene sulfonate powder market?

Key players include Concordia Pharmaceuticals, CMP Pharma, Mylan, Glenmark Pharmaceuticals, Sanofi, Teva Pharmaceuticals, Apotex, Aurobindo Pharma, Zydus Cadila, and Akorn.

Sources

  1. Market Research Intellect: Sodium Polystyrene Sulfonate Powder Market Size, Share & Growth.
  2. Drugs.com: Sodium polystyrene sulfonate Prices, Coupons, Copay Cards & Patient Assistance.
  3. Cognitive Market Research: Global Sodium Polystyrene Sulfonate Powder Market Report 2024.
  4. Extrapolate: 2022-2030 Global and Regional Sodium Polystyrene Sulfonate Powder Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report.
  5. Reports and Data: Sodium Polystyrene Sulfonate Powder Market.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.